Mani, Inc. (マニー株式会社), a leading manufacturer of surgical sutures, ophthalmic scalpels, and dental instruments, reported a strong full-year fiscal 2026 (2026年8月期) performance, driven by robust demand for its high-market-share products and successful operational reforms. The company’s revenue and profitability metrics rose sharply, with net profit increasing by 32.6% year-over-year (YoY).
Key Numbers (JPY billion)
| Metric | FY2026 (Actual) | YoY Change |
|---|---|---|
| Revenue | JPY 16.1bn | +8.7% |
| Operating Profit | JPY 5.10bn | +22.2% |
| Ordinary Income | JPY 5.62bn | +31.4% |
| Net Profit | JPY 3.90bn | +32.6% |
| Operating Margin | 31.6% | — |
| Equity Ratio | 92.2% | — |
Business Overview
Mani, Inc. is a global leader in the production of surgical sutures, ophthalmic scalpels, and dental instruments, with a strong presence in high-margin medical device markets. The company holds a dominant position in its core segments and has historically relied on overseas manufacturing for its legacy products.
Analysis
Mani, Inc. delivered a comprehensive improvement across all key financial metrics in FY2026. Revenue grew by 8.7% YoY to JPY 16.1bn, while operating profit surged by 22.2% to JPY 5.10bn. The company’s operating margin reached 31.6%, significantly outperforming the industry average of 6.0%, highlighting the high-value nature of its product portfolio and strong pricing power.
Next Year Guidance
| Metric | 2027 Forecast (JPY) | YoY Change |
|---|---|---|
| Revenue | 32.8bn | 100% |
| Operating Profit | 9.2bn | +9.4% |
| Ordinary Income | 8.95bn | +12.3% |
| Net Profit | 6.45bn | +38.9% |
Management has provided the above guidance for the next fiscal year. Investors should monitor the company’s progress against these targets.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.